Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Laurus Labs Receives Renewed Investment | Contract Pharma

What are you searching for?

Sign in
Breaking News

Laurus Labs Receives Renewed Investment

Warburg Pincus invests $92mn in the Indian maker of APIs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Laurus Labs Private Limited, a Visakhapatnam, India-based developer and manufacturer of active pharmaceutical ingredients (APIs), recently announced that an affiliate of Warburg Pincus, a global private equity firm, has acquired a minority stake in the company by investing approximately $92 million. Warburg Pincus joins Fidelity Growth Partners India (FGPI) and Boston-based Fidelity Biosciences, who led an earlier round of investment in 2012, as an investor in the company.

Laurus is a manufacturer of APIs for anti-retroviral (ARV), oncology, cardio-vascular, anti-diabetic therapeutic segments. The company also has a presence in nutraceuticals and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad. In addition to the API business, the company has a fast-growing contract manufacturing business that caters to several generic and global pharmaceutical companies.

Dr. Satyanarayana Chava, founder and chief executive officer of Laurus said, “Laurus is at an important juncture in its evolution, having built a strong reputation in product development and manufacturing, delivering high-quality products to its customers and establishing a track-record of strong financial performance. We are glad to partner with Warburg Pincus in this phase of our growth where we will seek to continue the thrust on innovation and manufacturing excellence in offering cost-effective products and services and foraying into new business segments. In addition to securing growth capital, we look forward to leveraging Warburg Pincus’ deep domain expertise and global network of relationships to help enter new markets and add to our customer base.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics